Some radiation secondary cancer considerations below. The complications of hormone therapy that most RO's employ, but don't discuss, is not covered. There is NO silver bullet, and suggesting that any of us recommend one treatment over another simply because that's the one we choose is insulting, at best.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074073/
Prostate
As already mentioned, prostate cancer is a good example of radiation-induced secondary cancers as surgery and RT both are equally efficacious for the treatment. Brenner et al. [42] have analyzed SEER database to compare second malignancy in prostate cancer patients who were treated with either surgery or RT. They inferred that RT for prostate cancer significantly increased the risk of second malignancies by approximately 6% (95% CI, 1%–11%) as compared to surgery (p = 0.02). Increased relative risk was 15% and 34% for those who survived ≥5 years and ≥10 years, respectively. Majority of the second cancers were bladder and rectal cancers. However, incidence of secondary lung cancer and sarcomas in radiation field also increased (lung received, 0.5 Gy). In a study to assess the impact of radiation among prostate cancer patients, overall rate of second solid cancer was similar in both 3D-CRT and conventional RT arm (RR = 1.00; 95% CI, 0.91-1.09) [43]. However, the risk of a second rectal cancer was significantly lower in the 3D-CRT arm as compared to conventional RT (RR = 0.59; 95% CI, 0.40–0.88). Rates of second cancer diagnosis (site specific solid cancer and leukemia) were equal for both higher and lower-energy RT (RR = 0.97; 95% CI, 0.89–1.06). When brachytherapy was compared to external beam RT (EBRT) patients, there were lower rates of second solid cancers overall (RR = 0.92; 95% CI, 0.83–1.02), significantly lower rates of second colon cancer (RR = 0.52; 95% CI, 0.37–0.73), and leukemia (RR = 0.60; 95% CI, 0.40–0.89).
https://link.springer.com/article/10.1007%2F
s00268-015-3324-x
Abstract
Literature about
the risk of secondary cancer after radiation therapy (RT) of prostate and rectal cancer reveals contradictory results. We conducted a meta-analysis to examine whether the RT induces secondary rectal or prostate cancer in patients, respectively, with prostate or rectal cancer. All studies published in Medline or Pubmed up to March 3, 2015, containing RT of primary rectal or prostate cancer, and providing risk estimates of secondary prostate or rectal cancer were considered as eligible. Relative risk (RR) and standardized incidence ratios (SIR) were calculated using the random-effects model. Twenty studies met the inclusion criteria. 12 of them were from the Surveillance, Epidemiology, and End Results (SEER) database. For prostate cancer patients, pooled adjusted RRs or SIRs did not show an effect on the risk of secondary rectal cancer. However, notwithstanding the limitations of SEER-based studies, the subgroup of prostate cancer patients receiving external beam radiation therapy (EBRT) showed an increased risk of rectal cancer. For rectal cancer patients, pooled adjusted RR of prostate cancer was 1.12 (95 % CI, 0.44–2.8) and SIR was 0.40 (95 % CI, 0.29–0.55). All studies included in the SIR analysis of rectal cancer were derived from the SEER data source. Based on current evidence, RT for prostate cancer patients had no effect on rectal cancer incidence, except for patients who received EBRT therapy. However, compared with the general population, RT for rectal cancer is associated with a decreased prostate cancer risk as found in SEER-based studies.
https://link.springer.com/article/10.1007%2F
s00268-015-3324-x
Abstract
Objectives
As the number of prostate cancer survivors is increasing, the long-term health of prostate cancer patients has become a significant health issue. Radiation is known to induce malignant transformation, and prostate cancer radiotherapy is suggested to induce secondary malignancies. This report reviews the available data regarding the risk of secondary cancer after radiation for prostate cancer.
Methods
Epidemiological studies of the secondary cancer risk in patients with a history of prostate cancer radiation and the literature regarding radiation-induced carcinogenesis were reviewed.
Results
Prostate cancer is not associated with an increased number of additional malignancies. The data suggests a modest increase in secondary cancers associated with radiation for prostate cancer, as approximately one in 70 patients undergoing radiation and surviving more than 10 yr will develop secondary cancer. The most common sites for secondary cancers are bladder and rectum. In addition to the cancers adjacent to the radiation field, there is also an increase of cancers in distant sites, such as lung. The increased risk for secondary cancers is reported after external radiation, not after brachytherapy. The available data originated from studies of patients undergoing conventional radiotherapy. New treatment methods, such as intensity-modulated radiotherapy, may be associated with a higher risk of secondary cancers.
Conclusion
Although the incidence of secondary cancers after prostate cancer radiotherapy is not dramatically different from the overall population, patients should be informed about
this risk. Other treatment modalities should be considered for patients with long life expectancy and for patients with additional risk factors.
https://www.renalandurologynews.com/home/news/urology/prostate-cancer/bladder-cancer-risk-higher-with-radiation-therapy-for-prostate-cancer/
In multivariable competing-risk analyses, EBRT was associated with a significant 35% increased risk of bladder cancer compared with RP, a team led by Marco Moschini, MD, PhD, of Luzerner Kantonsspital, Lucerne, Switzerland, reported in European Urology.
“This information should be discussed during the counseling of clinically localized PCa patients during the decision making regarding RP versus EBRT,” Dr Moschini and his colleagues concluded.
The study found no significant difference in the risk of rectal cancer between the treatment modalities.
The investigators identified their study population using the Surveillance, Epidemiology and End Results (SEER)-Medicare database. Of the 84,397 patients, 51,145 and 33,252 underwent EBRT and RP, respectively. The EBRT group was older than the RP group (median 74 vs 69 years). The median follow-up was 69 months, during which 1236 primary bladder cancers and 432 primary rectal cancers were diagnosed.
Reference
Moschini M, Zaffuto E, Karakiewicz PI, et al. External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: a population-based analysis. Eur Urol. 2018; published online ahead of print.
https://www.bmj.com/content/352/bmj.i851
In conclusion, we identified a possible association between radiotherapy and an increased odds of secondary cancers compared with no radiotherapy or with surgery. We identified consistent evidence of an increased risk of bladder, colorectal, and rectal cancers in men treated with radiotherapy. We did not find consistent evidence for an association between radiotherapy and secondary lung and hematologic cancers. Although there was an increase in risk, the absolute rates of these secondary cancers remain low, particularly compared with other rates of complications associated with treatment for prostate cancer. This information could be helpful in the decision making process regarding such treatment.
https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.16
Conclusions: EBRT-patients had a slightly higher SC-incidence than the general population. The rectal and urinary bladder cancer risk should be taken into account in follow-up after EBRT.
Adjusted risk analysis of second cancer (all and selected types) in 24155 radically treated prostate cancer patients.
ALL SECOND CANCER Multivariate analysis*
SHR (95 % CI) p-value
RP 1 .
EBRT 1.38(1.24-1.54) <0.001
RT after RP 1.21(0.98-1.50) 0.076
HDR-BT 1.18 (0.87-1.60) 0.297
COLON CANCER
RP 1 .
EBRT 1.06(0.80-1.41) 0.67
RT after RP 0.98(0.55-1.72) 0.94
HDR-BT 0.65(0.24-1.77) 0.40
RECTAL CANCER
RP 1 .
EBRT 1.72(1.15-2.57) 0.008
RT after RP 0.93(0.40-2.21) 0.881
HDR-BT 0.77(0.18-3.21) 0.719
BLADDER CANCER
RP 1 .
EBRT 1.38(1.24-1.54) <0.001
RT after RP 1.21(0.98-1.50) 0.076
HDR-BT 1.18(0.87-1.60) 0.297
LUNG CANCER
RP 1 .
EBRT 2.13(1.54-2.94) <0.01
RT after RP 1.32(0.68-2.54) 0.41
HDR-BT 2.81(1.44-5.49) 0.003
SARCOMA
RP 1 .
EBRT 3.25(0.63-16.8) 0.160
RT after RP NA** .
HDR-BT NA** .
https://www.cancernetwork.com/radiation-oncology/rt-prostate-cancer-linked-low-risk-secondary-cancers
For an individual prostate cancer patient, the results reported in this analysis warrant a discussion with his clinician, wrote the editorial authors, noting that secondary malignancies can be added to the list of avoidable adverse effects associated with the treatment of men with low-risk disease who likely need no treatment. But, they emphasized, these results do not impede the use of radiotherapy for men with high-grade, lethal disease who would benefit from such anticancer treatment
Good luck going forward....all is not as it would seem.
Post Edited (garyi) : 7/31/2019 5:08:40 PM (GMT-6)